Table 3.
Comparison of risk group categorization between the life-time breast cancer risk calculation including family history and mutation status and PRS311 (FH + PRS), the calculation including questionnaire-based risk factors and PRS (FH + QRF + PRS), and the calculation also including breast density (FH + QRF + PRS + BD) in women from whom breast density information was available.
|
Life-time breast cancer risk |
FH + PRS |
FH + PRS + QRF† |
FH + PRS + QRF + BD |
|||
|---|---|---|---|---|---|---|
| CHEK2 | non-CHEK2 | CHEK2 | non-CHEK2 | CHEK2 | non-CHEK2 | |
| ≤20 % | 2 | 8 | 3 | 8 | 5 | 9 |
| 20–30 % | 11 | 10 | 9 | 9 | 8 | 8 |
| ≥30 % | 27 | 0 | 28 | 1 | 27 | 1 |
| Of whom >50 % | 3 | 0 | 4 | 0 | 6 | 0 |
| Total number | 40 | 18 | 40 | 18 | 40 | 18 |
| Shifts in life-time risk category | ||||||
| From FH + PRS to other, n(%) | 8 (20.5) | 5 (27.8) | 8 (20.5) | 5 (27.8) | ||
| From FH + QRF + PRS to other, n(%)† | 9 (23.1) | 5 (27.8) | ||||
| Screening category change compared to FH + PRS | ||||||
| Upscaled, n(%) * | 4 (50.0) | 3 (60.0) | 5 (62.5) | 2 (40.0) | ||
| Downscaled, n(%)* | 4 (50.0) | 2 (40.0) | 3 (37.5) | 3 (60.0) | ||
| Screening category change compared to FH + PRS + QRF | ||||||
| Upscaled, n(%) * | 3 (33.3) | 2 (40.0) | ||||
| Downscaled, n(%)* | 6 (66.6) | 3 (60.0) | ||||
Differences in risk groups are shown for heterozygotes and non-carriers separately. The numbers of shifts might be different than expected from the presented data, as individual changes in risk category are not visible within this Table. † for one heterozygotes, relevant QRFs were not available, and therefore only data on FH + PRS were used and by definition they did not change category.